Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Pyxis Oncology (NASDAQ:PYXS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

Several other equities research analysts also recently weighed in on PYXS. Zacks Research downgraded Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Guggenheim increased their price target on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. HC Wainwright lifted their target price on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday. Finally, Stifel Nicolaus began coverage on shares of Pyxis Oncology in a report on Monday, November 3rd. They set a “buy” rating and a $9.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.20.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $1.63 on Friday. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.55. The business has a fifty day moving average price of $2.87 and a 200 day moving average price of $2.43. The stock has a market capitalization of $101.48 million, a P/E ratio of -1.02 and a beta of 1.44.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, equities research analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently made changes to their positions in PYXS. Bank of America Corp DE increased its position in Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after purchasing an additional 9,062 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Pyxis Oncology during the first quarter worth $81,000. Schulhoff & Co. Inc. boosted its position in shares of Pyxis Oncology by 125.4% during the second quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock worth $302,000 after buying an additional 153,000 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Pyxis Oncology during the 2nd quarter worth about $146,000. Finally, Catalyst Funds Management Pty Ltd acquired a new position in Pyxis Oncology during the 2nd quarter worth about $26,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.